phospholipids is mentioned 10 times in the Catalent patent
The lipids used in the dosage forms described herein can belong to the cationic lipids, glycolipids, phospholipids, glycerophospholipids, galactosylceramid, sphingolipids, cholesterol and derivatives thereof. Phospholipids may include, but are not limited to, phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, cardiolipin, and phosphatidylinositol with
virosome formulation Adjuvant (e.g. 3 M-052): 8-140 µg/ml Phospholipids: 0.5 to 5 mg/mL Sodium Chloride: 50-150 mM HEPES 10-50 mM Trehalose: 4-10% w/w pH 6.5 to 8.0varying fatty acyl compositions.
Although the optimal concentration of 3D-PHAD® in virosomes is not currently known pending further animal experiments, more control over the extent of 3D-PHAD® incorporation was desired. 3D-PHAD® is less soluble than phospholipids in organic solvents, with a solubility limit of around 1 mg/ml in chloroform/methanol 2:1, suggesting it is more amphiphilic. However, since DOPC and DOPE were incorporated into virosomes from a dry lipid film also containing 3D-PHAD®, while the adjuvant was not, the solubility of 3D-PHAD® in DCPC seemed limited. A solution of 3D-PHAD® in 100 mM of DCPC appeared clear, but when added to the viral supernatant and filtered, it did not lead to more incorporation. We suspect that the filtration removed aggregates or micelles of 3D-PHAD® which were not visible to the naked eye.
Results A novel chimeric influenza virosome was constructed containing the glycoprotein of Vesicular stomatitis virus (VSV-G), along with its own hemagglutinin protein. To optimize the transfection efficiency of both chimeric and influenza cationic virosomes, HEK cells were transfected with plasmid DNA and virosomes and the transfection efficiency was assessed by FACS analysis. The chimeric virosome was significantly more efficient in mediating transfection for all amounts of DNA and virosomes compared to the influenza virosome Chimeric influenza virosome, including VSV-G, is superior to the conventional influenza virosome for gene delivery. https://link.springer.com/article/10.1007/s10529-016-2108-1
Moreover, we incubated cationic VSV virosomes with a GFP-expressing bacmid and transfected sf9 cells, after 24?h some cells expressed GFP indicating the ability of VSV virosomes to deliver heterologous DNA to these cells. This is the first report of a virosome-based delivery system introduced for an insect cell line. https://www.tandfonline.com/doi/full/10.3109/08982104.2016.1144205
Samuel Z. Wilson's research while affiliated with Baylor College of Medicine and other places Samuel Z. Wilson's research works | Baylor College of ... www.researchgate.net/scientific-contributions/... Samuel Z. Wilson's research while affiliated with Baylor College of Medicine and ... with vesicular stomatitis virus (VSV) and exposed to different regimens of small particle aerosols of either ...
Vaccine technology has significantly evolved in the last decade, including the development of several RNA and DNA vaccine candidates, licensed vectored vaccines (e.g., Ervebo, a vesicular stomatitis virus [VSV]-vectored ebolavirus vaccine, licensed in the European Union), recombinant protein vaccines (e.g., Flublok, an influenza virus vaccine made in insect cells, licensed in the United States), and cell-culture-based vaccines (e.g., Flucelvax, an influenza virus vaccine made in mammalian cells). SARS-CoV-2 was identified in record time, and its genomic sequence was swiftly made widely available by Chinese researchers (Wu et al., 2020, Zhou et al., 2020, Zhu et al., 2020). In addition, we know from studies on SARS-CoV-1 and the related MERS-CoV vaccines that the S protein on the surface of the virus is an ideal target for a vaccine. In SARS-CoV-1 and SARS-CoV-2, this protein interacts with the receptor ACE2, and antibodies targeting the spike can interfere with this binding, thereby neutralizing the virus (Figure 1). The structure of the S protein of SARS-CoV-2 was solved in record time at high resolution, contributing to our understanding of this vaccine target (Lan et al., 2020a, Wrapp et al., 2020). Therefore, we have a target antigen that can be incorporated into advanced vaccine platforms. https://www.sciencedirect.com/science/article/pii/S1074761320301205
Market Data 
Markets 
AI
